Evidence map›Paper›PMID 36033800›Full record

ArticleFrontiers in public health2022

The burden of liver cirrhosis in mortality: Results from the global burden of disease study.

Fei Ye, Mimi Zhai, Jianhai Long, Yi Gong, Chutong Ren, Dan Zhang, Xiang Lin, Sushun Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Disrupted Gut Viral-Bacterial Ecology of Patients With Liver Cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Exploring Cirrhosis: Insights into Advances in Therapeutic Strategies.International journal of molecular sciences · 2025
    Review
  16. Where Do Patients With Cirrhosis Die? A CDC WONDER Analysis From 1999 to 2020.JGH open : an open access journal of gastroenterology and hepatology · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fei YeDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Mimi ZhaiXiangya Nursing School, Central South University, Changsha, China.
Jianhai LongDepartment of Respiratory, Beijing Tiantan Hospital, Capital Medicine University, Beijing, China.
Yi GongDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Chutong RenDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Dan ZhangClinical Nursing Teaching and Research Section, The Second Xiangya Hospital, Central South University, Changsha, China.
Xiang LinDepartment of General Surgery, The Huaihua Second People's Hospital, Huaihua, China.
Sushun LiuDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Liver cirrhosis-related death is a serious threat worldwide. The number of studies exploring the mortality trend of cirrhosis caused by specific etiologies was limited. This study aimed to demonstrate the pattern and trend based on the data of global burden of disease (GBD). Methods: The data of cirrhosis mortality were collected from the GBD 2017. The Age standardized mortality rate (ASR) and estimated annual percentage changes (EAPC) were used to estimate the temporal trend of liver cirrhosis mortality by etiologies, regions, sociodemographic index (SDI), and sexes. Results: Globally, mortality cases of cirrhosis increased by 47.15%. Although the global ASR of cirrhosis mortality remained stable during this period, the temporal trend varied in etiologies. The ASR of mortality caused by hepatitis C virus (HCV), alcohol consumption, and non-alcoholic steatohepatitis (NASH) increased with an EAPC of 0.17 (95% CI, 0.14-0.20), 0.20 (95% CI, 0.16-0.24), 1.00 (95% CI, 0.97-1.04), respectively. A decreasing trend of ASR was found among the causes of hepatitis B virus (BV) and other causes. The increased pattern was heterogeneous worldwide. The most pronounced increase trend was found in middle-high SDI regions and Eastern Europe. Contrarily, the most pronounced decrease trend was found in low SDI regions and Western Sub-Saharan Africa. Conclusion: Cirrhosis is still a public health problem. The growth trend of cirrhosis mortality caused by HCV was slowed by promoting direct-acting antiviral therapy. Unfortunately, we observed an unfavorable trend in etiologies for alcohol consumption and NASH, which indicated that more targeted and specific strategies should be established to limit alcohol consumption and promote healthy lifestyles in high-risk countries, especially in middle-high SDI regions and Eastern Europe.

Indexed as

Hepatitis CHepatitis C, ChronicNon-alcoholic Fatty Liver DiseaseAntiviral AgentsGlobal Burden of DiseaseGlobal HealthHumansLiver CirrhosisAntiviral AgentsASREAPCglobal burden of disease studyliver cirrhosismortality

Identifiers

PMID36033800
PMCPMC9403789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.